

Comparative effectiveness of different acupuncture therapies for neck pain

Hyo-Rim Jo, KMD, BSc^a, Eun-Ji Noh, KMD, BSc^b, Se-Hee Oh, KMD^c, Seong-Kyeong Choi, KMD, BSc^d, Won-Suk Sung, KMD, PhD^d, Su-Ji Choi, KMD, PhD^e, Dong-II Kim, KMD, PhD^e, Seung-Ug Hong, KMD, PhD^c, Eun-Jung Kim, KMD, PhD^{f,*}

Abstract

Background: Neck pain is a common musculoskeletal symptom that has negative effects on quality of life and work productivity. Acupuncture has been widely used for neck pain, and a number of randomized controlled trials (RCTs) and systematic reviews (SRs) have evaluated its effectiveness. However, previous studies have obtained inconsistent results regarding the effects of acupuncture for neck pain, and there is no SR for the comparative efficacy and safety of various types of acupuncture. Therefore, we herein conducted a SR and network meta-analysis to compare and rank different types of acupuncture with respect to their effectiveness in treating neck pain.

Methods: We searched 9 electronic databases for relevant RCTs published from their inception to July 1, 2021. Pairwise metaanalyses and network meta-analysis were performed with R software using the frequentist framework. Change of pain intensity was assessed as the primary outcome, and change of pain-related disability and efficacy rate were assessed as secondary outcomes. The Cochrane risk of bias tool and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) instrument were used to evaluate the quality of the included RCTs and the certainty of the evidence.

Results: A total of 65 RCTs involving 5266 participants and 9 interventions were included. Three network meta-analyses were constructed for the following: pain intensity (42 RCTs, 3158 participants), pain-related disability (21 RCTs, 1581 participants), and efficacy rate (40 RCTs, 3512 participants). The results indicated that fire acupuncture, electroacupuncture, and warm acupuncture were more effective than manual acupuncture in terms of pain intensity reduction and efficacy rate, and that electroacupuncture decreased pain-related disability more effectively than manual acupuncture. Fire acupuncture ranked first among the 9 interventions. The overall q of evidence was very low according to the GRADE assessment. The reported adverse events were not serious.

Conclusion: Fire acupuncture, warm acupuncture, acupoint catgut embedding, and electroacupuncture ranked higher than other interventions (usual care, sham acupuncture, no treatment) in reducing the pain and disability index scores and the efficacy rate. However, the included trials were evaluated as being of low quality; thus, we recommend additional well-designed RCTs with larger sample sizes to confirm these findings.

Systematic review registration: PROSPERO, CRD42021235274.

Abbreviations: 95% CI = 95% confidence interval, ACE = acupoint catgut embedding, EA = electroacupuncture, FA = fire acupuncture, GRADE = Grading of Recommendations Assessment, Development and Evaluation, IL = interleukin, MA = manual acupuncture, NDI = Neck Disability Index, NPQ = Neck Pain Questionnaire, NRS = Numeric Rating Scale, NT = no treatment, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, RCT = randomized controlled trial, RR = relative risk, SA = sham acupuncture, SMD = standardized mean difference, SR = systematic review, SUCRA = cumulative ranking under the surface curve, UC = usual care, VAS = Visual Analog Scale, WA = warm acupuncture, WM = western medicine.

Key Words: acupuncture, neck pain, network meta-analysis, systematic review, randomized controlled trials

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI19C0142, HF20C0210).

The authors have no funding and conflicts of interest to disclose.

Data and material from this trial are available upon reasonable request and approval by the corresponding author.

Supplemental Digital Content is available for this article.

^a Department of Acupuncture & Moxibustion, College of Korean Medicine, Dongguk University Graduate School, Seoul, Republic of Korea, ^b Department of Obstetrics & Gynecology, College of Korean Medicine, Dongguk University Graduate School, Seoul, Republic of Korea, ^c Department of Ophthalmology, Otolaryngology and Dermatology, Dongguk University Ilsan Oriental Hospital, Gyeonggi-do, Republic of Korea, ^a Department of Acupuncture & Moxibustion, Dongguk University Bundang Oriental Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea, ^e Department of Obstetrics & Gynecology, Dongguk University Ilsan Oriental Hospital, Gyeonggi-do, Republic of Korea, and ^r Department of Acupuncture & Moxibustion, Dongguk University, Seoul, Republic of Korea. *Correspondence: Eun-Jung Kim, KMD, PhD, Department of Acupuncture & Moxibustion, Dongguk University Bundang Oriental Hospital, 268, Buljeong-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea (e-mail: hanijjung@ naver.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Jo H-R, Noh E-J, Oh S-H, Choi S-K, Sung W-S, Choi S-J, Kim D-I, Hong S-U, Kim E-J. Comparative effectiveness of different acupuncture therapies for neck pain. Medicine 2022;101:33(e29656).

Received: 1 September 2021 / Received in final form: 8 January 2022 / Accepted: 11 January 2022

http://dx.doi.org/10.1097/MD.000000000029656

1. Introduction

Neck pain is defined as pain, muscle tension, or stiffness that is anatomically localized below the superior nuchal line and above the scapular line from the back, and below the superior nuchal line and the external occipital protuberance line and above the superior border of the clavicle and the suprasternal notch from the side and front.^[1] A large proportion of the population (22–70%) suffers from neck pain at some point in the lifespan, and the prevalence of neck pain increases with age.^[2] The pain and disability related to neck pain can considerably impact an individual's quality of life and work productivity and increase the global burden of health care expenditure.^[3]

Most patients with neck pain receive conservative treatments, such as oral medication, injection, massage, and/or physical therapy unless they have cervical fracture or severe cervical neuropathy.^[2] However, some of these treatments have limited evidence supporting their efficacy against neck pain and/or carry potential complications, such as the elevated risk for cardiovascular disease, renal toxicity, nerve injury, infection, epidural hemorrhage, and/or subarachnoid penetration.^[4–6]

Acupuncture is widely used to treat musculoskeletal pain in many countries.^[7,8] An estimated 3 million American adults receive acupuncture treatment each year for musculoskeletal pain, which is the most common condition treated by this modality in the United States.^[9] One study conducted in 15 European countries found that 13% of patients with pain seek acupuncture treatment in addition to conventional medication.^[10] According to clinical practice guidelines for neck pain using traditional Korean medicine, various acupuncture therapies, including manual acupuncture (MA), electroacupuncture (EA), warm acupuncture (WA), fire acupuncture (FA), and acupoint catgut embedding (ACE), can relieve symptoms related to neck pain.^[11]

While a number of randomized controlled trials (RCTs), systematic reviews (SRs), and meta-analyses have reported pairwise comparisons of different types of acupuncture or acupuncture versus an inactive control,^[11-13] the existing literature does not allow us to compare the effectiveness of various types of acupuncture therapies. Furthermore, in some SRs, the results regarding the effects of acupuncture treatment were observed inconsistently depending on which comparison group was designated.^[13-13] Therefore, the literature does not currently provide clinicians with clear guidelines on what types of acupuncture therapies are most effective in treating neck pain.

Network meta-analysis is a quantitative synthesis of evidence for various treatments of the same indication; it combines direct and indirect evidence into a single analysis of potential treatment effect and allows the user to rank the available treatments according to the effect size.^[16] Thus, network meta-analysis could be used to evaluate the relative effectiveness of different types of acupunctures, even if the interventions have never been compared directly in clinical trials.

Here, we used frequentist network meta-analysis to compare and rank the effectiveness and safety of different types of acupuncture therapies and other interventions for treating neck pain.

2. Methods

This SR and network meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement and PRISMA extension for network meta-analyses.^[17,18] This study was registered on PROSPERO under number CRD42021235274, and a detailed protocol was published elsewhere.^[19]

2.1. Search strategy

Ovid-MEDILINE, EMBASE, Cochrane library, China National Knowledge Infrastructure (CNKI), Korea Med, Korean medical database (KMBASE), Korean Studies Information Service System (KISS), ScienceON, and Oriental Medicine Advanced Searching Integrated System (OASIS) were searched on July 1, 2021, with the limitation of Chinese, English, and Korean language. We used the following combination of MeSH terms and free words to search the literature: (1) neck-pain-related terms (such as neck pain, cervical pain, cervicodynia, cervicalgia, cervical intervertebral disc displacement/degeneration, cervical spondylosis), (2) various acupuncture treatments (such as manual acupuncture, electroacupuncture, warm acupuncture, fire acupuncture, acupoint catgut embedding), and (3) randomized controlled trial. The search strategy was initially developed for the Ovid-MEDILINE databases; we subsequently adjusted it to the requirements of the other databases. In addition, missing literature was included from the reference lists of the retrieved SRs (see Appendix S1, Supplemental Digital Content, http:// links.lww.com/MD/G898, which shows the detailed retrieval strategies for all databases).

2.2. Eligibility criteria

2.2.1. *Participants.* Patients who had cervical pain or cervical intervertebral disc herniation with or without radicular symptoms and aged 18 years above were enrolled, regardless of gender, disease course, or disease severity. Only patients lacking a specific reason for the condition (e.g., whiplash or traumatic injury) were included.

2.2.2. Intervention and comparison. We included 5 types of acupuncture therapies: MA, EA, WA, FA, and ACE. In this network meta-analysis, each acupuncture treatment defined only a single use of these 5 types, as this allowed us to compare the effects of different acupuncture treatments for neck pain. As comparators, we included sham acupuncture (SA), usual care (UC), western medicine (WM), no treatment (NT; wait list), and one of the abovementioned acupuncture therapies.

2.2.3. Outcome measures. The included studies were required to have one of the following outcomes: (i) as a primary outcome, pain intensity measured by the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS); and (ii) as secondary outcomes, pain-related disability evaluated by the Neck Disability Index (NDI) or Neck Pain Questionnaire (NPQ), and the efficacy rate.

2.3. Study selection and data extraction

All identified studies were imported into Endnote X20 (ISI Research Soft, USA). The titles and abstracts were read and studies that were duplicate or did not meet the inclusion criteria were excluded. For each identified study, 2 reviewers (E-J Noh and S-H Oh) reviewed the full text and extracted the data using a standardized extraction table. At either stage, any discrepancy in the study inclusion or data extracted was resolved by a third reviewer (H-R Jo).

Study characteristics (author and year of publication), sample size, age, intervention, comparator, treatment frequency, duration, outcomes, results, and adverse events were recorded. Means and standardized differences at baseline and the end point of the treatment period were extracted.

2.4. Quality assessment

Two reviewers (S-J Choi and D-I Kim) independently used the risk of bias tool of Cochrane Collaborations to evaluate the methodological quality of the included studies. Each study was rated as high, low, or unclear for the following 7 domains: random sequence generation, allocation concealment, participant and personnel blinding, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. A third reviewer (H-R Jo) resolved any disagreement as necessary.

2.5. Statistical analysis

All analyses were performed in R software (http:// www.r-project.org/; version 4.0.3) using the "meta" and "netmeta" packages. A randomized effects model was used to perform a pairwise meta-analysis for each pair of interventions, applying the standardized mean difference (SMD), relative risk (RR), and 95% confidence interval (CI) to synthesize dichotomous or continuous outcomes. Heterogeneity was evaluated by the I^2 value, with $I^2 < 50\%$ taken as representing little or no obvious heterogeneity. A network meta-analysis was performed using a frequentist method. League tables and P-scores were used to present the ranking of direct and indirect effect estimates and the 95% CI for all comparisons of interventions in the network. According to Rücker et al, the P-score can be interpreted as a cumulative ranking under the surface curve (SUCRA) for frequentist analysis.^[20] We first evaluated the difference between direct and indirect evidences for the same comparison, using global I^2 and Pvalues, and then assessed the inconsistency for each intervention using the node-splitting analysis method.

2.6. GRADE assessment

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was used to evaluate the quality of evidence for each outcome. Based on the assessment of each study limitation, inconsistency, indirectness, imprecision, and publication bias, the quality of the evidence can be maintained or downgraded to moderate, low, or very low quality.^[21] Given that the quality of evidence might differ across paired comparisons, a GRADE approach previously adapted for network meta-analysis was used for each pairwise comparison.^[22,23]

2.7. Publication bias and sensitivity analysis

We evaluated the small-sample effect or publication bias in each network meta-analysis by comparison-adjusted funnel plots. In addition, we conducted a sensitivity analysis by excluding studies with a higher risk of bias or a smaller sample size (<10 per group).

2.8. Ethics approval

No ethical approval was not needed because data from previously published studies in which informed consent was obtained by primary investigators were retrieved and analyzed.

3. Results

3.1. Search results

In total, 5217 RCTs were retrieved from the database searches and a further 15 studies were added manually. After the article title and abstract were read, 4371 duplicate records were removed and 694 records that did not meet the inclusion criteria were removed. Based on full-text assessments, a further 102 articles were discarded for the reasons listed in Figure 1. Eventually, 65 studies were included in the network meta-analysis (Fig. 1).




Figure 1. Flow chart of article searching and selection.

3.2. Characterization of the included RCTs

The 65 selected RCTs included a total of 5266 participants and had sample sizes varying from 17 to 220 patients. Most were conducted in China; of the others, 6 were conducted in Iran,^[24-29] 3 in Spain,^[30-32] 2 in Turkey,^[33,34] and 1 each from Taiwan,^[35] Japan,^[36] Germany,^[37] Korea,^[38] Belgium,^[39] and the United States.^[40] Sixty-two were 2-arm trials and the remaining 3 were 3-arm trials. Nine interventions were applied, including 6 types of acupuncture therapies (MA, EA, WA, FA, ACE, SA), WM, NT (waitlist), and UC (exercise, pressure release, Kinesiotaping). The treatment period of intervention ranged from 1 day to 9 weeks. Pain intensity was reported in 42 studies; of them, 39 used VAS and 3 used NRS. Pain-related disability was reported in 21 studies; of them, 11 used NDI and 10 used NPQ. The efficacy rate was reported in 41 studies. The characteristics of the included studies are presented in Table 1.

3.3. Risk of bias and quality assessment

The quantitative results of our risk of bias assessment are presented in Figures 2 and 3. Forty-two RCTs were rated as having a low risk of bias in random sequence generation: Of them, 26^[25,30-33,35-38,40,41,45,47,51, 53,54,60,62-64,67,71,74,79,87,88] used various computerized randomization programs, 11[43,44,50,55,58,66,68, ^{72,78,81,85]} used random number tables, 3^[27-29]used coin tossing, and 2^[24,39] used block randomization. In terms of allocation in the RCTs, 19 studies^[24,26,30-32,38-41,45,58,62,64,67,71,79,84,87,88] described proper allocation concealment (the use of sealed envelopes or independent researchers). Because of the nature of the interventions, performance bias was high in most studies; only 2 studies^[41,47] were assessed as having a low risk of bias in participant blinding due to the use of nonpenetrating SA. The detection bias had low risk in 12 RCTs^[26,30-33,37-41,47,52] that used independent assessors. Six RCTs^[33,37,39,43,45,84] were rated as high risk for attrition bias because they had large amounts of missing data, and 6 RCTs^[27,34,51,59,61,86] were rated as having unclear risk of bias for attrition because the reasons for the missing data were not stated. Ten RCTs^[28,42,43,47,50,53,58,63,69,87] did not report complete results, and therefore were assessed as a high risk for bias in selective reporting. One study^[36] that had volunteer bias was judged to have high risk of other bias.

3.4. Pairwise meta-analysis

3.4.1. Pain intensity. Fourteen pairwise meta-analyses were performed to compare the effectiveness of different acupuncture therapies in reducing pain intensity. MA was more effective in reducing pain intensity than SA (5 RCTs, SMD –1.11, 95% CI: -1.78 to -0.43; *P* = .0013) and UC (6 RCTs, SMD -0.59, 95% CI: -1.08 to -0.10; P = .0176). EA significantly reduced pain intensity compared to UC (1 RCT, SMD -0.75, 95% CI: -1.28 to -0.23; P = .0050). Compared to MA and other acupuncture therapies, WA, FA, and ACE had significantly better effects on pain intensity reduction (4 RCTs, SMD -0.96, 95% CI: -1.24 to -0.68, P < .0001; 1 RCT, SMD -1.76, 95% CI: -2.08 to -1.43, P < .0001; and 4 RCTs, SMD -0.67, 95% CI: -1.18 to -0.17, P = .0091, respectively). WA was more effective in reducing pain intensity compared to EA (3 RCTs, SMD -0.61, 95% CI: -1.22 to -0.00, P = .0486). When compared to NT, SA was significantly better at relieving pain intensity (1 RCTs, SMD -0.52, 95% CI: -1.02 to -0.01, P = .0439). There were obvious heterogeneities ($I^2 > 50\%$) in the above pairs, except for the comparison between WA and MA. There was no statistically significant difference between MA and WM, MA and NT, EA and SA, EA and NT, or EA and MA (Table 2).

3.4.2. Pain-related disability. Eleven pairwise meta-analyses were generated to investigate the ability of different acupuncture

therapies to reduce pain-related disability. MA reduced disability significantly more than SA (1 RCT, SMD –0.78, 95% CI: –1.10 to –0.45; P < .0001). EA showed a significantly greater reduction in disability compared with NT (1 RCT, SMD –1.02, 95% CI: –1.72 to –0.32; P = .0044) and MA (5 RCTs, SMD –2.18, 95% CI: –3.53 to –0.83; P = .0016). Compared to MA and the other acupuncture therapies, WA and ACE significantly decreased disability (2 RCTs, SMD –0.68, 95% CI: –1.02 to –0.34; P < .0001; and 2 RCTs, SMD –0.31, 95% CI: –0.53 to –0.10; P = .0046, respectively). FA was more effective in reducing pain-related disability compared with EA (1 RCT, SMD –0.60, 95% CI: –1.12 to –0.08; P = .0228). Comparing EA ($I^2 = 95.6\%$) with MA showed obvious heterogeneity. The remaining 5 pairs were not statistically different in pain-related disability (Table 3).

3.4.3. *Efficacy rate.* Twelve pairwise meta-analyses were performed to compare the efficacy rates of different acupuncture treatments. Compared to MA and other acupuncture treatments, EA, WA, FA, and ACE each yielded a significantly higher efficacy rate (15 RCTs, RR 1.12, 95% CI: 1.08 to 1.17; P < .0001, $I^2 = 0\%$; 5 RCTs, RR 1.13, 95% CI: 1.06 to 1.20; P = .0003, $I^2 = 4.4\%$; 2 RCTs, RR 1.28, 95% CI: 1.16 to 1.42; P < .0001, $I^2 = 0\%$; and 7 RCTs, RR 1.12, 95% CI: 1.05 to 1.20; P = .0009, $I^2 = 42.4\%$, respectively). The remaining 8 pairs were not statistically different in their efficacy rates (Table 4).

3.5. Results of network meta-analysis

3.5.1. Network plot for different interventions. In the network plot, the thickness of an edge represents the number of studies comparing 2 given interventions. Forty-two studies covering 9 interventions and 3158 participants with neck pain were included in the network meta-analysis for pain intensity (Fig. 4A). Pain-related disability was reported in 21 studies covering 9 interventions and 1581 participants (Fig. 4B), and the efficacy rate was reported in 40 studies covering 8 interventions and 3512 participants (Fig. 4C).

3.5.2. Evaluation of statistical inconsistency. The results of the consistency tests for pain intensity, pain-related disability, and the efficacy rate did not show statistically significant heterogeneity (P = .6848, .2138,and .7169, respectively, and thus > 0.05 for all); therefore the consistency model was selected. All local inconsistency tests were performed with net-split analysis. The net-split analyses for pain intensity, pain-related disability, and the efficacy rate yielded P values > .05, indicating that there was no significant difference between direct and indirect effect estimates for any of the intervention comparisons.

3.5.3. *Pain intensity.* A league table was established to compare effectiveness in relieving pain intensity among 9 interventions (Table 5). FA, WA, ACE, and EA more effectively lowered pain intensity than SA or UC, and MA was only more effective than SA (last row and third-to-last rows of Table 5, respectively). FA, WA, ACE, and EA significantly reduced pain intensity compared with NT (second-to-last row of Table 5). FA, WA, and EA had significantly better effects in reducing pain intensity compared with MA (fourth-to-last row of Table 5).

The P score denotes the probability that 1 intervention is more effective than the others.^[20] The network meta-analysis for pain intensity demonstrated the following ranking of P scores for the interventions: FA (P = .9397), WA (P = .8582), ACE (P = .7176), EA (P = .6845), WM (P = .4562), MA (P = .4260), UC (P = .1861), NT (P = .1368), and SA (P = .0947).

3.5.4. Pain-related disability. For pain-related disability, the network meta-analysis involved data from 21 RCTs covering 9 interventions (Table 6). The results showed that FA, EA, and WA were more effective in lowering pain-related disability compared

	- - -			Intervention		Tuesday			
	sample size	Mean age (yrs)	Experimental	al	Frequency,	Ireatment period			Adverse
Study ID	(E/C)	(E/C)	group	Control group	duration	(weeks)	Outcome	Results	event (n)
Acupuncture Ho 2017 ^[41]	77/77	$45.53 \pm 8.74/44.51 \pm 9.48$	MA	SA	3 times per week, 30 min	2	VAS, NPQ, SF-36	1. VAS: E > C (<i>P</i> < .001) 2. NPQ: E > C (<i>P</i> = .008)	No serious AEs. E: local transient
Tekin 2013 ⁽³³⁾	22/17	42.9±10.9/42.0±12.0	MA	SA	Twice per week (2 weeks), once per week (until end point)	4	VAS, SF-36	3. SF-36: E > C (<i>P</i> = .003) 1. VAS: E > C (<i>P</i> = .000)	Druises (n = 1.1) NR
Chou 2011 ^[35]	15/15	$34.1 \pm 10.7/33.9 \pm 8.3$	MA	SA	NR	1 day	NRS, PPT, ROM, mean amblitude of EPN	2. SF-36: E > C (<i>P</i> < .05) 1. NRS: E > C	NR
Nabeta 2002 ^[36]	17/17	34.2±10.8/30.8±12.0	MA	SA	Once a week, 5 min	ო		2. PPT: $E > C$ 3. ROM: $E > C$ 4. Mean amplitude of EPN : E > C (all $P < .05$) 1. VAS: $E = C$ 2. PDT: $E > C (P > .05)$	R
Irnich 2001 ^[37]	56/61	$52.3 \pm 13.3 / 52.2 \pm 13.2$	MA	SA	5 times, 30 min	с	VAS, ROM, SF-36	2. ROM: E = C 2. ROM: E = C	No serious AEs. Mild reactions
									(sweating, low blood pressure): E ($n = 17$), C ($n = 12$)
Raeissadat 2018 ^[24]	23/22	$41.6 \pm 6.8/39.4 \pm 7.7$	MA	WM (2cc of 2% lidocaine injection)	Once per week	S	VAS, PPT, ROM, NDI	3. SF-36: E = C 1. VAS: E < C	No serious AEs.
								2. PPT; E < C	E: local transient flare reaction (n = 1)
Wang 2015 ^{/421}	51/47	43±12/48±9	MA	WM(medical solution 2 mL injection; 2.5 mL of 2% lidocaine, 500 mg of mecobalamin, 2.5 mg of dexamethasone sodium phosphate, 12 mL of 0.9% saline)	5 times per week, 30 min	2	VAS, rotate-cervix test positive, dizziness score, efficacy rate	3. R0M: E < C 4. NDI: E < C (all <i>P</i> > .05) 1. VAS: E > C	No serious AEs.

Sample size size bioly Mean age (vrs) (F/C) Experimental group Cho 2014 ¹⁹⁰¹ 15/15 39.1±9.0/ 38.2±10.2 MA W Cho 2014 ¹⁹⁰¹ 15/15 39.1±9.0/ 38.2±10.2 MA W Fu 2005 ¹⁴³¹ 55/47 34.20±7.61/35.24±6.67 MA W Fu 2005 ¹⁴³¹ 55/47 34.20±7.61/35.24±6.67 MA W Altabalee 20120/20 23.6±1.61/7 MA W G Altabalee 2019 ¹⁵⁴¹ 20/20/20 23.6±1.61/7 MA U U Arias-Buria 2021 ¹⁰¹ 37/38 40.62±8.52/47.32±1.0.23 MA U U Arias-Buria 2020 ¹⁰¹ 15/15 21±3/22±2 MA U U Arias-Buria 2020 ¹⁰¹ 15/15 21±3/22±2 MA U U	Intervention					
(E/G) (E/G) (E/G) $group$ al 15/15 39.1 ± 9.0' MA al 15/15 38.2 ± 10.2' MA al 55/47 34.20 ± 7.61/35.24 ± 6.67 MA al 55/47 34.20 ± 7.61/35.24 ± 6.67 MA al 20/20/20 $C1:23.5 \pm 1.6.2$ MA al 23/38 40.652 ± 8.52/47.32 \pm 10.23 MA al 23/38 40.652 ± 8.52/47.32 \pm 10.23 MA al 23/38 40.652 ± 8.52/47.32 \pm 10.23 MA al 21 ± 3/22 \pm 2 MA MA al 20/20 ¹⁰ 15/15 21 ± 3/22 \pm 2 MA al 2006 ± 9.87/ MA MA al 20.52 ± 8.57/47.32 \pm 10.23 MA MA al 20.20 ¹⁰ 15/15 21 ± 3/22 \pm 2 MA al 20.51 ± 3/22 \pm 8.57 MA MA al 20.52 36.1 \pm 10.77 MA al 20/25 ± 8.57 MA MA <		Frequency,	Treatment period			Adverse
15/15 39.1±9.0/ 38.2±10.2 MA 15/47 34.20±7.61/35.24±6.67 MA 55/47 34.20±7.61/35.24±6.67 MA 55/47 34.20±7.61/35.24±6.67 MA 7338 34.20±7.61/35.24±6.67 MA 73738 34.20±7.61/35.24±6.67 MA 715 21:23.5±1.6 MA 7138 40.62±8.52/47.35±1.023 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA 16/17 30.06±9.877 MA 16/17 30.16±9.877 MA 16/17 30.15±8.33 MA 40.5±8.33 36.1±10.77 MA	group Control group	duration	(weeks)	Outcome	Results	event (n)
15/15 39.1±9.0/ 38.2±10.2 MA 55/47 34.20±7.61/35.24±6.67 MA 55/47 34.20±7.61/35.24±6.67 MA 55/47 34.20±7.61/35.24±6.67 MA 37/38 34.20±7.61/35.24±6.67 MA 37/38 20.20/20 23.6±1.81/ MA 37/38 40.62±8.52/47.32±1.023 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA 16/17 30.06±9.87/ MA 20/22 36.1±10.7/ MA 40.5±8.33 36.1±10.7/ MA					2. Rotate-cervix test positive: $E > C$	Subcutaneous blood stasis in
55/47 34.20±7.61/35.24±6.67 MA 55/47 34.20±7.61/35.24±6.67 MA 20/20/20 23.6±1.81/ MA C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 C1: 23.5±1.6 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA	MA WM (zaltoprofen 80 mg daily, 2 times per devi	3 times per week, 15 min	ę	VAS, NDI, BDI, SF-36, EO.ED	3. Dizziness score: $E > C$ 4. Efficacy rate: $E > C$ (all $P < .05$) 1. VAS: $E = C$	None None
55/47 34.20±7.61/35.24±6.67 MA 1 20/20/20 23.6±1.81/ MA 21 23.5±1.6 MA 37/38 20.52.39±3.09 MA 37/38 40.62±8.52/47.32±10.23 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA 16/17 26.5±8.57 MA 26.5±8.57 36.1±10.77 MA 40.5±8.33 30.15±8.33 MA					2. NDI: E = C 3. BDI: E = C 4. SF-36: E = C 5. FD-5D-F = C	
 20/20/20 23.6±1.81/ C1: 23.5±1.6 23.5±1.6 C1: 23.5±1.6 MA 7/38 40.62±8.52/47.32±10.23 MA 15/15 21±3/22±2 MA 15/15 21±3/22±2 MA 15/15 16/17 20.6±9.87/ 26.5±8.57 MA 16/17 20.22 36.1±10.7/ 40.5±8.3 MA 		d Twice a week,	4	efficacy rate, VAS, PRI, dizziness score	1. Efficacy rate: E > C	None
 20/20/20 23.6±1.81/ C1:23.5±1.6 37/38 20.22:23.9±3.09 37/38 40.62±8.52/47.32±10.23 15/15 21±3/22±2 15/15 21±3/22±2 15/15 21±3/22±2 MA MA 15/15 21±3/22±2 MA MA MA 15/15 30.05±9.877 MA <li< td=""><td></td><td>30 min</td><td></td><td></td><td>(P = .006) 2. VAS: E = C 3. PRI: E > C (P < .05) 4. Dizziness score: E > C (P</td><td></td></li<>		30 min			(P = .006) 2. VAS: E = C 3. PRI: E > C (P < .05) 4. Dizziness score: E > C (P	
37/38 C2: 23.9 ± 3.09 MA 15/15 40.62 ± 8.52/47.32 ± 10.23 MA 15/15 21 ± 3/22 ± 2 MA 16/17 21 ± 3/22 ± 2 MA 16/17 26.5 ± 8.57 MA a 20/22 36.1 ± 10.77 MA	MA C1: UC (Pressure release) C2: WM((Phonophoresis with betamethasone)	Twice per week, No retention	3–4 (7 times)	ROM, PPT, VAS	1. ROM: E = C2 > C1 2. PPT: E = C2 > C1	NR
15/15 21±3/22±2 MA 15/17 21±3/22±2 MA 16/17 30.06±9.87/ MA 26.5±8.57 MA a 20/22 36.1±10.7/ A 20/22±8.3 40.5±8.3	3 MA UC	Twice per week	9	NDI, Neck pain and disability scale	3. VAS: $E = C2 > C1$ (all $P < .001$) 1. NDI: $E = C$	None
15/15 21±3/22±2 MA 16/17 30.06±9.87/ MA 26.5±8.57 MA 36.1±10.7/ MA 40.5±8.3				, ,	2. Neck pain and disability scale: $\vec{E} = C$	
16/17 30.06±9.87/ MA 26.5±8.57 MA 20/22 36.1±10.7/ MA 40.5±8.3	MA UC (pressure release)	1 time,	1 day	NRS, NDI, inspiratory vital capacity	1. NRS: E = C	None
$16/17$ $30.06 \pm 9.87/$ MA 26.5 ± 8.57 MA $20/22$ $36.1 \pm 10.7/$ MA 40.5 ± 8.3 40.5 \pm 8.3		no retention			 NDI: E = C Inspiratory vital capacity: E > C (P < 05) 	
20/22 $36.1 \pm 10.7/$ MA 40.5 ± 8.3	MA UC (pressure release)	3 times per week, no retention	, -	VAS, DASH, NPQ	1. VAS: $E > C$ ($P = .02$) 2. DASH: $E = C$ 3. NDO: $E = -C$	NR
	MA UC (pressure release)	Once per week,	4	NDI, NRS, PPT, tone, elasticity, stiffness	1. NDI: $E = C$	No serious AEs.
		No retention			2. NRS: $E = C$	E: postneedling soreness
					 3. PPT: E = C 4. Tone: E = C 5. Elasticity: E = C 6. Stiffness: E = C) 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

				Intervention					
	Sample				•	Treatment	-		:
Study ID	size (E/C)	wean age (yrs) (E/C)	experimental group	al Control group	Frequency, duration	perioa (weeks)	Outcome	Results	adverse event (n)
Ziaeifer 2016 ⁽²⁸⁾	14/17	$30.78 \pm 10.39/26.69 \pm 9.4$	MA	UC (ischemic compression)	3 times per week (48-hour interval between	-	VAS, PPT	1. VAS: E < C 2. PPT: E < C	NR
Hayta 2016 ^[34]	28/27	NR	MA	UC (Kinesiotaping)	Twice per week	2	VAS, NDI, Nottingham Health Profile	1. VAS: E = C	NR
					10-20 min			2. NDI: E = C 3. Nottingham Health Profile:	
Ziaeifer 2014 ^[29]	16/17	$30.06 \pm 9.87/26.50 \pm 8.57$	MA	UC (ischemic compression)	3 times per week, no retention	-	VAS, PPT, DASH	E = C 1. VAS: E > C (<i>P</i> = .01) 2. PPT: E = C 3. DASH: E = C	NR
Fu 2013 ⁽⁴⁴⁾	30/30	41.53±9.41/42.57±10.32	MA	UC (McKenzie exercise)	5 times per week, 30 min	0	Efficacy rate, cervical spine function assessment (total, clinical symptoms, clinical examination, daily life actions)	1. Efficacy rate: $E > C (P < .05)$	Ч
								2. Cervical spine function assessment - Total score: $E > C$ ($P < .001$) - Clinical symptoms: E > C (P < .05) - Clinical examination: E > C (P < .05)	
Mejuto-Vazquez 2014 ^[31]	8/6	$25 \pm 4/24 \pm 7$	MA	NT	No retention	1 day	NRS, PPT, ROM	1. NRS: $E > C$ ($P < .01$)	No serious AEs.
								2. PPT: E > C (<i>P</i> < .01)	E:postneedling soreness (n = 8)
otroacununcture	a							3. ROM: E > C (P < .01)	
Chen 2019 ^[40]	46/33/30	mean 55/ C1: mean 53/ C2: mean 51	EA	C1: SA C2: NT	Twice per week, 30 min	n	VAS, SF-36	1. VAS E = C1 E > C2 (P - 002)	No serious AEs. E: acupuncture- related
								C 7 05 (V = 2000) C1 = C2 2. SF-36 - physical functioning, pain E = C1	(n = 1)

www.md-journal.com

Sumple star (EO) Tentention (EO) Internation (EO) Single Holl (EO) 37:00 67:00-11(5) EA) A PO) POO POO<	Table 1 (Continued)									
Statute Manual statut					Intervention					
Cull 2016 ¹¹ 3730 47.135 H H H J V Cull 2016 ¹¹	Study ID	sample size (E/C)	Mean age (yrs) (E/C)	Experiment: group		Frequency, duration	Ireatment period (weeks)		Results	Adverse event (n)
E Ci E Ci E Ci E									C1 = C2 - role functioning/ohysical	
CH 2010 37/30 47/05:14.14 EA SA 31ms par week, 30 min A Mounting senderative senderati									E = C1 $E > C2 (P - 032)$	
Dut 2016 ¹⁴ 37201 4.7.03:4.1.1.0y 4.2.7.3:1.0.16 E.4 S.4 3.1mes per week.30 min 4 RPD, RPD, SF-58, FE = 2, FE =									E ≥ ∪E (F = .U3E) C1 = C2	
OutOrDH ⁴¹ 3730 4703±14190 EA SA 31miss perveex, 30 min 4 Non.MPG E-61 E-627 = 007 Mod E-62 E-627 = 007 Mod E-62 E-62 E-62 Mod E-62 E-62 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td> role functioning/emotional, social functioning, emotional </td> <td></td>									 role functioning/emotional, social functioning, emotional 	
Cui 2016** 37/30 47/35 ± 14.19 4827 ± 10.96 EA SA 3 times per week. 00 min 4 MPD, MPD, SF, 64 EC (P = .00) E = .01 Feng 2014** 17/18/19 20-60 EA 3 times per week. 00 min 4 A MPD, MPD, SF, 64 1. MPC, E= C MP Feng 2014** 17/18/19 20-60 EA 21 mins per week. 00 min 4 MPD, MPD, SF, 64 1. MPC, E= C MP Zhang 2014** 103/103 men 45.8 EA 5. MPD, MPD, SF, 64 1. MPC, E= C MP Zhang 2014** 103/103 men 45.8 EA 3. times per week, 45 min 3 A MPD, MPD, SF, 64 2. MPD, E= C MP Zhang 2014** 103/103 men 45.8 EA 3. times per week, 45 min 3 A MPD, MPD, E> C = C = 2. diff > C = C = C = C = C = C = C = C = C = C									well-being	
Late Total 47.03-14.19/ (2014) EA SA 31miss per week, 30 min 4 NO, MFO, SF-36, 10-00 (2014) F= 00 (2014) Feng 2014 ¹⁴ 17/18/19 20-60 EA 31miss per week, 30 min 4 NO, MFO, SF-36, 10-00 (2014) 1 2									E = 01 E = C2	
Cli 2016 rd 37/30 47/03.14.19/ 4.9.27.4.10.96 EA SA 3 times per week, 30 min 4 NP0, MP0, SF-36, 1.1PC, E = C1 NP0, MP0, SF-36, 2.2PG, E = C1 NP0, MP0, SF-36, 3.5F-36, E = C1 NP0, MP0, SF-36, 3.5F-36, E = C1 NP1, MP0, SF-36, E = C1 NP1, MP0, SF-36, E = C1 NP1, SF-36, E = C1 SF-36, E = C1 SF-36, E = C1 SF-36, E = C1 NP1, SF-36, E = C1 SF-36, E =									C1 = C2 - Energy/fatigue	
Cui 2016 ⁴¹ 37/30 47/30±14.19/ 47/30±14.19/ 47/30±14.19/ EA SA 3 times per week, 30 min 4 NPO, MPO, SF-36, med 27/40 Cui = 0.2 (1 + 0.2) = 0.3 Eng 2014 ⁴¹ 17/18/19 20-60 EA Ci : SA 3 times per week, 30 min 4 NPO, MPO, SF-36, med 45 1. MPO, E = C NPO Zang 2014 ⁴¹ 17/18/19 20-60 EA Ci : SA 3 times per week, 30 min 4 NPO, MPO, SF-36, mean 45.8 1. MPO, E = C NPO Zang 2013 ⁴¹¹ 17/18/19 20-60 EA Ci : SA 3 times per week, 30 min 4 NPO, MPO, SF-36, mean 45.8 NPO 1. MPO, MPO, SF-36, mean 45.8 NPO Zang 2013 ⁴¹¹ 103/103 mean 45.8 EA SA									E = C1 E > C2 (P = .007)	
Cull 2018 ¹⁴ 37/30 47/03±14.19/ 4927±1096 EA SA 3 times per week. 30 min 4 NP0, MP0, SF-36, fer contraction E - C2 (P - contraction) Find 17/18/19 20-60 EA C1: SA 3 times per week. 30 min 4 NP0, MP0, SF-36, fer contraction 2 MP0. E = C MP0. MP0, SF-36, fer contraction 3 mP0. E = C Find 17/18/19 20-60 EA C1: SA 3 times per week. 30 min 4 NP0, MP0, WS, PP1 2 MP0. E > C = C Zhang 2013 ^{4/10} 103/103 mean 45.8 EA SA 3 times per week. 45 min 3 NP0, MP0, WS, PP1 2 MP0. E > C = C Zhang 2013 ^{4/10} 103/103 mean 45.8 EA SA 3 times per week. 45 min 3 NP0, Symptom score, 1 NP0. E = C Zhang 2013 ^{4/10} 103/103 mean 45.8 EA SA 3 mP0. E = C 2 Symptom score, E = C									с 2 С (– :00.) С1 = С2 - reneral health F – С1	
Cul 2016 ¹⁶ 37/30 47.05±14.15V EA SA 3 times per week, 30 min 4 NP0, MP0, SF-36, 1, NP0, TE = C Nu Fing 2014 ⁴⁴ 17/18/19 20-60 EA CI:SA 3 times per week, 30 min 4 NP0, MP0, MS, PPT 2 HP0, E > C MP0, E > C 2 HP0, E > C 1 HP0, TE > C 2 HP0, E > C = C 2 HP0, E > C 2 HP0, E > C = C									E > C2 (P = .03)	
17/18/19 20-60 EA C1:SA 3 times per week. 30 min 4 NP0, MS, PP1 3:-56:E = C 4	6 Cui 2016 ^[45]	37/30	47.03±14.19/ 40.27±10.06	EA	SA	3 times per week, 30 min	4	NPQ, MPQ, SF-36, efficery rate	1. NPQ: $E = C$	None
17/18/19 20-60 EA C1: SA 3 times per week, 30 min 4 NP0, VAS, PP1 1. NP0: E > C1 = C2 NNP0, VAS, PP1 1. NP0: E > C1 = C2 3. NNP0, E > C1			00.01						2. MPQ: E = C	
17/18/19 20–60 EA C1: SA 3 times per week, 30 min 4 NPO, MPO, WS, PPT 1. HPD: E > C1 = C2 NF $C2: NT$ $C2: NT$ $C2: NT$ $2. MPO, E > C1 = C2$ NF $3: MS: E > C1 = C2$ $3: MS: E > C1 = C2$ NF $3: MS: E > C1 = C2$ $3: MS: E > C1 = C2$ $NPO, SMPIon Score$ $1. MPO. E = C1 = C2$ $3: MS: E > C1 = C2$ $3: MS: E > C1 = C2$ $2: Symptom score$ $1. MPO. E = C$ $MPO_{ST} = SCI = C2$ $2: SYmptom score E = C 2: Symptom score E = C EI P = SCI = C2 P = SCI = C2 $									o. or-oo. c = o 4. Efficacy rate: E = C	
103/103 mean 45.8 EA SA 3 times per week, 45 min 3 NPQ, symptom score, 1. NPQ: E = C2 (all $P < .05$) No SF-36 2. Symptom score, 1. NPQ: E = C E_{14} Provide score, 2. Symptom score E = C E_{14}	Feng 2014 ^[46]	17/18/19	20-60	EA	C1: SA C2: NT	3 times per week, 30 min	4	NPQ, MPQ, VAS, PPT	1. NPQ: E > C1 = C2 2. MPQ: E > C1 = C2	NR
103/103 mean 45.8 EA SA 3 times per week, 45 min 3 NPQ. symptom score; Ivo R-36 2. Symptom score; 2. 2. Symptom score; E 1									3. VAS: $E > C1 = C2$ 4. PPT: $E > C1 = C2$ (all $P < .05$)	
2. Symptom score: E = C Eii	Zhang 2013 ^[47]		mean 45.8	EA	SA	3 times per week, 45 min	С	NPQ, symptom score, SE-36	1. NPQ: E = C	No serious AEs.
(n = 1), peadoche (n = 2), edizziness (n = 1), pain at acupuncture point (n = 1), local transient bruises(n = 2), chestoliscomfort (n = 1)								5	2. Symptom score: E = C	E:increased neck
Inecacacine necocacine (n=2), edizariees (n=1), pain et acupuncture point (n=1), local transiert bruises(n=2), chest disconfort (n=1)										pain (n = 1),
(n = 1), pain at accounture point transient but ises(n = 2), cheat disconnord (n = 1)) (craft transient but ises(n = 2), cheat disconnord (n = 1) (craft)										neadache (n - 2)
(n = 1), pain at acupuncture point (n = 1), local transient bruises(n = 2), chest discomfort (n = 1) (Continued)										(II – 2), dizziness
acupunctire point (n = 1),local transient bruises(n = 2), cheat discomfort (n = 1)										(n = 1), pain at
(Continued)										acupuncture
transient transient bruises(n = 2), chest disconfort (n = 1) (Continued)										pullit. (n = 1).local
bruises(n = 2), cheat disconfort (n = 1) (Continued)										transient
(n = 1) (Continued)										bruises(n = 2), chest discomfort
Continued)										(n = 1)
										(Continued)

Table 1 (Continued)									
				Intervention					
Study ID	Sample size (E/C)	Mean age (yrs) (E/C)	Experimental group	al Control group	Frequency, duration	Treatment period (weeks)	Outcome	Results	Adverse event (n)
								3. SF-36: E = C	C:increased neck pain $(n = 2)$, headache (n = 1), dizziness (n = 1), itching palm $(n = 1)$, warmth at the
Li 2008 ^[48]	42/52	E: 47.40 ± 8.75	EA	WM (Fenbid capsules 300 mg, once a day)	Once every other day, 20 min	က	efficacy rate	1. Efficacy rate: $E > C (P < .05)$	back (n = 1) NR
Yan 2006 ⁽⁴⁹⁾	78/78	u: NK mean 48.5/47.3	EA	WM (Ibuprofen 2 tablets, enteric-coated aspirin tablets 0.3g, vitamin B1,	Once per day, 30 min	10 days	efficacy rate	1. Efficacy rate: $E > C (P < .01)$	NR
Diethelm 2014 ^[50]	30/30	$42.27 \pm 11.79/50.77 \pm 10.79$	EA	zumg, twice per day) UC (Kinesiotaping)	Twice per week, 30 min	4	VAS, MPQ, efficacy rate	1. VAS: $E > C$ ($P = .016$) 2. MPQ: $E > C$ ($P < .01$) 3. Efficiency rate: $E > C$ ($P < .05$)	NR
Yang 2020 ^[51]	30/30	total 47.63±3.72	EA	MA	3 times per week, 30 min	4	Cervical spondylosis symptom scale, VAS, NDI, Serum	3. Lineary rate: $L > 0$ ($N > 00$) 1. Cervical spondylosis symptom scale: $E > C (P < 01)$	R
Garcia-De-Miguel 2020 ¹³²	22/22	24.14±9.39/ 25.45±8.53	EA	MA	1 time,	1 day	VAS, NDI, PPT, ROM, Side bending	2. VAS: $E > C$ ($P < .01$) 3. NDI: $E > C$ ($P < .01$) 4. Serum IL-6 ($P < .01$) 5. Efficacy rate ($P < .05$) 1. VAS: $E = C$	R
					E: 20 min, C: no retention		strengtn	2. NDI: $E > C (P < .05)$ 3. PPT: $E > C (P < .01)$ 4. ROM: $E = C$	
Huang 2018 ^{is2]}	45/45	41±10/42±9	EA	MA	once every other day, 20 min	С	symptom and physical sign score, VAS, efficacy rate	 Side bending strength: E = C Symptom and physical sign score: E > C 	NR
Chen Y 2016 ^[53]	30/30	mean 45/45	EA	MA	once every other day, 30 min	4	TTYS, MPQ, efficacy rate	2. VAS: E > C 3. Efficacy rate: E > C (all $P < .05$) 1. TTYS: E > C ($P < .05$)	None
							2	2. MPQ: E > C (<i>P</i> < .05) 3. Efficacy rate: E > C (<i>P</i> < .05)	

Sample size Study ID Mean age (vrs) (E/C) Chen G 2016 ^[64] 30/30 32.83±8.94/34.66±8.92 Tian 2015 ^[54] 30/30 39.12±7.85/41.33±9.33 Chen 2015 ^[54] 30/30 39.12±7.85/41.33±9.33 Liu 2015 ^[54] 30/30 39.12±7.85/41.33±9.33 Liu 2015 ^[54] 30/30 39.12±7.85/41.33±9.33 Liu 2015 ^[54] 30/30 39.12±7.85/41.33±9.33	I							
16 ^[54] 30/30 [59] 30/30] ^{59]} 30/30		Experimental group	Control group	Frequency, duration	Treatment period (weeks)	Outcome	Results	Adverse event (n)
30/30	36 ± 8.92	EA	MA	once per day, 30 min		PPI, PRI, VAS, ROM, efficacy rate, symptom and sion score	1. PPI: E > C 2. PRI: E > C	M
30/30						2	3.VAS: $E > C$ 4. ROM: $E > C$ 5. Efficacy rate: $E > C$ 6. Symptom and sign score: $E > C$	
30/30	33±9.33	EA	MA	once per day, 30 min	4	NPQ, MPQ efficacy rate	1. NPQ: $E > C (P < .01)$ 2. MPQ: $E > C (P < .01)$ 3. Fflicacy rate: $F = C$	NR
30/30		EA	MA	once per day, 30 min	4	efficacy rate, PRI, VAS, PPI, mean treatment time	1. Efficacy rate: E = C	NR
30/30							2. PHI: $E > C$ ($P < .01$) 3.VAS: $E > C$ ($P < .01$) 4. PPI: $E > C$ ($P < .01$) 5. Mean treatment time: $E > C$ ($P < .01$)	
	33±11.37	EA	MA	once per day, 30 min	ო	symptom and sign score, MPQ, F wave conduction velocity (median nerve, ulnar nerve), efficaor rate	1.Symptom and sign score: E > C	Н
							2. MPQ: $E > C$ 3. F wave conduction velocity: E > C 4. Efficacy rate: $E > C$ (all $P < O5$)	
Jin 2013 ^[58] $30/30$ $44.60 \pm 1.78/41.10 \pm 1.94$	0 ± 1.94	EA	MA	once per day, 30 min	5	efficacy rate, PRI, VAS, PPI, TTYS	1. Efficacy rate: E = C 2. PRI: E = C	No serious AEs. Anxiety in both groups.
Zhang 2011 ⁵⁹ 57/49 21–77		EA	MA	once per day, 30 min	n	efficacy rate, curative	3. VAS: $E = C$ 4. PPI: $E = C$ 5. TTYS: $E > C (P < .05)$ 1. Efficacy rate: $E = C$	NR
Yang 2011 ^[60] 36/36 42.18/41.32	2	EA	MA	5 times per week, 30 min	4	vAS, efficacy rate	2. Curative rate: $E > C \ (P < .05)$ 1. VAS: $E > C \ (P < .01)$	NR

Medicine

(naniiiinno)										
				Inte	Intervention	1				
0	Sample size	Mean age (yrs)	Experimental	tal	anter Contract	Frequency,	period		n ann tha	Adverse
	(E/U)	(E/U)	group		CONTROL GROUP	aurauon	(weeks)	outcome	Results	event (n)
Ji 2015 ⁽⁶¹⁾	29/29	NR	EA	MA		5 times per week, 30 min	4	NPQ, VAS, SF-36	2. Efficacy rate: E > C (<i>P</i> < .05) 1. NPQ: E > C 2. VAS: E > C3. SF-36: E > C	NR
Wang 2010 ^[62]	35/35	38.29±10.72/36.96±11.21	EA	MA		once every other day, 20 min	10 days	NPQ, MPQ, VAS, SF-36. efficacy rate	(all $P < .05$) 1. NPQ: $E > C (P < .01)$	None
									2. MPO: $E > C$ ($P < .01$) 3. VAS: $E > C$ ($P < .01$) 4. SF-36: $E > C$ ($P < .05$) (except physical functioning and role physical: $E = C$) 5. Efficacy rate: $E > C$ ($P = .03$)	
Liu 2010 ^[63]	30/30	$40.93 \pm 11.25/42.03 \pm 11.61$	EA	MA		once per day, 30 min	Ю	symptom and sign score, efficacy rate. PRI	1.Symptom and sign score: E > C	NR
								- - - -	2. Efficacy rate: $E > C$ 3. PRI: $E > C$ (all $P < .05$)	
Lai 2010 ^[64]	35/35	NR	EA	MA		once per day,	4	symptom score, Chinese medicine		None
								symptom score, VAS, PRI, PPI,	1. Symptom score: E > C	
						20 aim		emcacy rate	O Obiación modición o matem	
									2 Cuntese meaticine symptom score: $E > C$ 3. VAS: $E > C$ 4. PRI: $E > C$ 5. PPI: $E > C (1-5 all P < .01)$	
Yang 2009 ⁶⁵¹	100/100	23-77	EA	MA		once per day, 30 min	10–30 days	10-30 days efficacy rate, curative rate	0. Ellicacy rate: $c = 0$ 1. Efficacy rate: $E > C$ 2. Curative rate: $E > C$ (all $P < 05$)	NR
Ding 2009 ^[66]	30/30	$41.05 \pm 9.65/42.50 \pm 7.63$	EA	MA		5 times per week, 30 min	Ċ	symptoms scores, efficacy rate	1. Symptoms scores: $E > C (P < .01)$	RN
Yu 2007 ^[67]	30/30	$46.19 \pm 10.88/43.64 \pm 14.63$	EA	MA		once per day,	က	symptom and sign score, PRI, VAS, PPI, efficacy rate	 2. Efflicacy rate: E > C (P < .05) 1. Symptom and sign score: E > C (P < .05) 	NR
						30 min			2. PRI: $E > C$ ($P < .001$) 3. VAS: $E > C$ ($P < .05$) 4. PPI: $E > C$ ($P < .001$) 5. Efficacy rate: $E > C$ ($P < .05$)	

Table 1

				Inter	Intervention					
Chudu ID	Sample size /r. /r./	Mean age (yrs)	Experimental	tal	Control or sources	Frequency,	Treatment period	t Outnomo	Docution	Adverse
Warm acupuncture Chen 2020 ^[68]	4	NR NR	WA AW	MA		once every other day, 20–30 min	9	eff	1. Efficacy rate: E > C	None
Ju 2019 ⁶⁹¹	60/60	48.55±11.63/46.27±11.51	WA	MA		E: once per week, 20 min	(n	SF-36, NPQ, VAS assessment scale for cervical spondylosis, improvement index,	2. Symptoms score: $E > C$ 3. NPQ: $E > C$ 4. VAS: $E > C$ 5. SF-36: $E > C$ (all $P < .05$) 1. Assessment scale for cervical spondylosis: $E > C$ ($P < .01$)	None
						C: 6 times per week, 30 min		improvement rate, symptom score, VAS	 Improvement index: E = C Improvement rate: E = C Symptom score: E > C (P 	
Xu 2017 ^[70]	110/110	56.2±9.4/ 56.4+03	WA	MA		twice per day	5	efficacy rate, VAS	 < .0.1) 5. VAS: WA > MA(<i>P</i> < .01) 1. Efficacy rate: E > C 2. VAS: E > C fall <i>D</i> < .05) 	NR
Guo 2015 ^[71]	30/30	$24.07 \pm 3.41/24.70 \pm 2.95$	WA	MA		once every other day, 30 min	2	NPQ, MPQ, efficacy	1. NPQ: $E > C (P < .05)$	None
Zhou 2014 ⁷²¹	30/30	mean 39.2/43.3	WA	MA		once per day,	10 days	eff	2. MPQ: $E > C$ ($P < .01$) 3. Efficacy rate: $E > C$ ($P < .05$) 1. Efficacy rate: $E > C$	None
Lin Z 2012 ^[73]	40/40	mean 60.25/58.24	WA	MA		30 min once every other day	0	vAS TTYS, efficacy rate	2. TTYS: E > C3. VAS: E > C (all P < .05) 1. TTYS: E > C (P < .05) 2. Efferment rate: E - C	NR
Garov 2016 ^[74]	30/30	$42.81 \pm 12.76/40.45 \pm 12.99$	WA	EA		5 times per week, 30 min	0	TTYS, VAS	2. Lillbacy late. L = C 1 TTVS · E = C	E: subcutaneous bleeding (n = 1), burn (n = 1)C:
Su 2015 ⁷⁹	30/30	39±11/44±12	WA	EA		once every other day, 20 min	\sim	2	2. WAS: E = C 1. PRI: E > C	suboutaneous bleeding $(n = 1)$, dizziness $(n = 1)$ NR
								or red and yenow tender points		

Medicine

Table 1 (Continued)										
	-			Intervention	ention					
Study ID	sample size (E/C)	Mean age (yrs) (E/C)	Experimental group		Control group	Frequency, duration	Ireatment period (weeks)	n Outcome	Results	Adverse event (n)
Lin J 2012 ^[76]	30/30	18- 18- 18-	M	E		once everv ofther dav. 30 min	4	VAS. NPO. efficaev	 2. VAS: E > C 3. PPI: E > C 4. Efficacy rate: E > C 5. The counts of red tender points: E > C 6. The counts of yellow tender points: E > C (all P < .05) 1. VAS: E > C (P = .01) 	endo
				I				rate	2. NPQ: $E > C$ ($P = .04$) 3. Efficacy rate: $E = C$	
Lire acupuncture Qui 2015 ^[77]	31/31	44.12±11.21/	FA	MA		E: twice per week, no retention	с С	symptom and sign scores, efficacy rate	1. Symptom and sign score: $E > C (P < .05)$	NR
Sun 2015 ⁷⁸	100/100	43.58±10.02 46±12/46±14	FA	MA		C: once per day, 30 min once per day E: no retention C: 20 min	က	I, PRI, rate	2. Efficacy rate: $E > C (P < .05)$ 1. VAS: $E > C$ 2. PPI: $E > C$ 3. PRI: $E > C$ 4. Efficacy rate: $E > C$	N
Zhao 2013 ^[79]	30/30	18-60	FA	EA		E: once per 5 days, no retention	4	MPQ, NPQ, NDI, EMG (trapezius muscle, stemocleidomastoid muscle), efficacy rate	1. MPQ: $E > C (P < .01)$	NN
-						C: once per day, 30 min			2. Mro. $E > C(P < .01)$ 3. NDI: $E > C(P < .05)$ 4. EMG: $E = C$ 5. Efficacy rate: $E > C(P < .01)$	
Acupoint catgut emoedoing Cheng 2018 ^[80] 73/73	mbeaaing 73/73	52.8±5.2/	ACE	MA		E: once every 15 days	4	symptoms scores, efficacy rate	1. Symptoms scores: $E > C$ ($P < .05$)	R
Qui C 2015 ^[81]	63/63	51.5 ± 5.2 $38 \pm 8/37 \pm 9$	ACE	MA		C: once per day, 30 min E: once per 2 weeks C: once per day 20–30 min	4	efficacy rate	2. Efficacy rate: $E > C$ ($P < .05$) 1. Efficacy rate: $E > C$ ($P < .05$)	R
Wang 2016 ^[82]	35/35	mean 52/54	ACE	MA		E: once per week	с	symptom and sign score, VAS, PPI, efficaev rate	1.Symptom and sign score: $E = C$	NR
						C: once per day, 20 min			2. VAS: E = C 3. PPI: E > C (P < .05) 4. Efficacy rate: E > C (P < .05)	

Jo et al. • Medicine (2022) 101:33	
------------------------------------	--

				Inter	Intervention					
Shirdv ID	Sample size (F./C)	Mean age (yrs) /F./C)	Experimental	a	Control aroun	Frequency, duration	Treatment period (weeks)	Outrome	Recuits	Adverse
Li 2015 ^[83]	43/43	56.3 + 8.5/ 57.1 + 7.3	ACE	MA	450	E: once per week	4	clinical symptoms and		NB
								function evaluation, VAS, PRI, PPI, efficacy rate	 Clinical symptoms and function evaluation: E > C 	
						C: once per day, 30 min			2. VAS: E > C 3. PRI: E > C 4. PPI: E > C 5. Efficacy rate: E > C (all <i>P</i>	
Zhao 2015 ^[84]	60/60	$27.5 \pm 2.4/28.0 \pm 2.6$	ACE	MA		once per day C: 30 min	10 days	efficacy rate	< .05) 1. Efficacy rate: $\vec{E} > C (P < .01)$	NN S
	Z9/8C	29 ± 8/30 ± 9	ACE	MA		E: once per week C: once per day, 30 min	2	efficacy rate, NUI, VAS	1. Emicacy rate: E > C 2. NDI: E > C3. VAS: E > C (all	Ĭ
Feng 2012 ^[86]	117/98	38.9±7.6/ 40.1±8.7	ACE	MA		E: once per 2 weeks C: once everv other dav. 30 min	4	NDI, VAS	P < .05) 1. NDI: E > C ($P < .05$) 2. VAS: E > C ($P < .05$)	NR
Xian 2012 ^[87]	30/30	$48.70 \pm 7.15/47.53 \pm 7.31$	ACE	MA		E: once per week	2	Cervical spondylosis score, MPQ, efficacy rate	1. Cervical spondylosis score: E $> C (P = .01)$	No serious AEs.
						C: 6 times per week, 30 min			2. MPQ: E > C (<i>P</i> < .01)	E:subcutaneous bleeding
Zou, 2016[88]	30/20	<u>1067+705/5073+760</u>	JUV	VIV		E. and har weak	~	Carvinal	3. Efficacy rate: $E > C$ ($P = .01$)	(n = 2) MB
							÷	spondylopathy symptoms and function evaluation scale, MPQ, efficaev rate	1. Cervical Spondylopathy Symptoms and Function Evaluation Scale: $E > C$ ($P = .03$)	-
						C: once per day, 15–20 min			2. MPQ: $E > C$ ($P = .03$) 3. Efficacy rate: $E > C$ ($P = .03$)	

14




Figure 2. Risk of bias graph.

to UC (last row of Table 6). EA more effectively reduced disability compared to MA (second-to-last row of Table 6).

The network meta-analysis for pain-related disability showed the following ranking of P scores for the interventions: FA (P = .8867), EA (P = .7933), WA (P = .7050), WM (P = .5295), ACE (P = .4350), SA (P = .4263), NT (P = .3666), MA (P = .2535), and UC (P = .1042).

3.5.5. Efficacy rate. Twelve RCTs covering 8 interventions reported on the efficacy rate (Table 7). FA, WA, ACE, and EA were significantly more effective compared to UC, WM, and MA alone (second-, third-, and fourth-to-last rows of Table 7, respectively). FA had a higher efficacy rate than EA or ACE (second and third rows of Table 7, respectively).

The network meta-analysis for efficacy rate demonstrated the following ranking of P scores for the interventions: FA (P = .9864), WA (P = .7951), ACE (P = .6961), EA (P = .6128), MA (P = .3725), WM (P = .2205), UC (P = .1678), and SA (P = .1489).

3.6. Safety

Overall, 24 RCTs including 1852 patients reported on the safety of interventions, as shown in Table 1. Thirteen RCTs showed no adverse events^[26,30,38,43,45,53,62,64,68,69,71,72,76]; the 11 studies in which adverse events were observed included the interventions of MA, SA, WM, EA, ACE, and WA. Acupuncture most frequently caused minor subcutaneous bleeding or bruises at the acupuncture point. Soreness and discomfort at acupuncture points, sweating, low blood pressure, headache, dizziness, and chest pain were also reported. For WM, subcutaneous bruises were reported after injection.^[42] These intervention-related adverse reactions were not serious and resolved without treatment.

3.7. Publication bias and sensitivity analysis

Funnel plots and the *P* value for the Egger test were used to visually inspect and assess the symmetry of network meta-analyses (Fig. 5). The funnel plot for the pain-related disability network was visually asymmetrical and the *P* value for its Egger test was < 0.05 (P = .0384), indicating the presence of potential publication bias. While the funnel plot and *P* value of the Egger test (P = .2269) demonstrated no strong evidence of publication bias across pain intensity, it revealed a scattered distribution that may be related to the obvious heterogeneity between studies.

We conducted a sensitivity analysis by excluding 3 studies^[31,42,43] that had 3 high-risk bias in risk of bias tool or had a very small-sample size (number per group < 10). This did not change the P-score ranking: FA had the highest P-score for reducing pain intensity (*P* = .9305), followed by WA (*P* = .8491), ACE (*P* = .6983), EA (*P* = .6697), WM (*P* = .5091), MA (*P* = .3984), UC (*P* = .1892), NT (*P* = .1716), and SA (*P* = .0841).

3.8. GRADE assessment

The GRADE approach was used to evaluate study limitations, inconsistency, indirectness, imprecision, and publication bias. Overall, the certainty of the evidence for pain intensity, pain-related disability, and efficacy rate was "very low," "very low," and "low," respectively. This reflected that most of the included studies had high risk of bias and serious imprecisions (see Appendix S2–S4, Supplemental Digital Content, http://links.lww.com/MD/G898, which show details on the GRADE assessment for all pairwise comparisons).

4. Discussion

Numerous studies have assessed the efficacy and safety of acupuncture for treating neck pain, but the literature has lacked a direct comparison of RCTs between different acupuncture methods. This has limited the ability of clinicians to choose the best treatment from empirical information. Here, we used the network meta-analysis method to compare and rank different types of acupuncture for their ability to reduce pain intensity and pain-related disability, as well as their efficacy rate for treatment of neck pain.

In this SR and network meta-analysis, we combined direct and indirect evidence from 65 studies covering 5266 participants with neck pain. We compared the effectiveness of different acupuncture options by assessing pain intensity, pain-related disability, and the efficacy rate. Our network meta-analyses showed that FA, WA, ACE, and EA were more effective in relieving neck pain intensity compared to UC and SA; MA reduced pain intensity more than SA alone; and FA, WA, and EA reduced pain intensity more than MA. In terms of reducing pain-related disability, FA, EA, and WA were more effective than UC, and EA was superior to MA. In terms of the efficacy rate, FA, EA, ACE, and EA outperformed MA, WM, and UC; and FA was more effective than ACE and EA. Consequently, in terms of the efficacy rate and the ability to reduce overall symptoms, FA, EA, and WA were more effective than UC; and EA was more effective than MA.

In our 3 network meta-analyses, FA, WA, ACE, and EA generally had high rankings; there was no significant difference between them, probably due to the small number of direct comparisons. Among them, FA was considered to be the best performing option in terms of symptom relief and efficacy rate of neck pain treatment. Several studies^[89,90] have suggested that FA can trigger the rapid absorption of inflammatory factors (e.g.,





interleukin [IL]-1, IL-6, IL-1 β , and tumor necrosis factor- α) in the diseased area through the surrounding lymphoid tissue and may control the central nervous system. This could account for the ability of FA to reduce neck-pain intensity and neck-pain-related disability.

Table 2	
Pairwise meta-analysis of pain intensity.	

Comparison	Number	SMD (95% CI)	Р	ľ
MA vs SA	5	-1.11 [-1.78, -0.43]	.0013	86.6%
MA vs WM	5	0.01 [-0.39, 0.40]	.9753	63.7%
MA vs UC	6	-0.59 [-1.08, -0.10]	.0176	67.0%
MA vs NT	2	-0.71 [-1.83, 0.40]	.2102	68.6%
EA vs SA	1	-0.09 [-0.53, 0.36]	.7086	-
EA vs UC	1	-0.75 [-1.28, -0.23]	.0050	-
EA vs NT	2	-1.00 [-2.02, 0.01]	.0525	80.8%
EA vs MA	12	-0.75 [-1.57, 0.07]	.0739	95.5%
WA vs MA	4	-0.96 [-1.24, -0.68]	<.0001	49.8%
WA vs EA	3	-0.61 [-1.22, -0.00]	.0486	74.4%
FA vs MA	1	-1.76 [-2.08, -1.43]	<.0001	-
ACE vs MA	4	-0.67 [-1.18, -0.17]	.0091	85.5%
WM vs UC	1	-1.16 [-1.83, -0.48]	.0008	-
SA vs NT	1	-0.52 [-1.02, -0.01]	.0439	-

Т	а	b	le	3	
	e.	9	e	3	

Pairwise meta-analysis of pain-related disability.

Comparison	Number	SMD (95% CI)	Р	ľ
MA vs SA	1	-0.78 [-1.10, -0.45]	<.0001	_
MA vs WM	2	0.55 [-0.22, 1.31]	.1607	59.7%
MA vs UC	4	-0.40 [-1.13, 0.33]	.2792	83.0%
EA vs SA	3	-0.31 [-0.77, 0.15]	.1815	63.3%
EA vs NT	1	-1.02 [-1.72, -0.32]	.0044	-
EA vs MA	5	-2.18 [-3.53, -0.83]	.0016	95.6%
WA vs MA	2	-0.68 [-1.02, -0.34]	<.0001	0%
WA vs EA	1	-0.34 [-0.85, 0.17]	.1968	-
FA vs EA	1	-0.60 [-1.12, -0.08]	.0228	-
ACE vs MA	2	-0.31 [-0.53, -0.10]	.0046	0%
SA vs NT	1	-0.12 [-0.76, 0.53]	.7199	-

 $\label{eq:ACE} \begin{aligned} \mathsf{ACE} &= \mathsf{acupoint}\ \mathsf{catgut}\ \mathsf{embedding},\ \mathsf{CI} &= \mathsf{confidence}\ \mathsf{interval},\ \mathsf{EA} &= \mathsf{electroacupuncture},\ \mathsf{FA} &= \mathsf{fire}\\ \mathsf{acupuncture},\ \mathsf{MA} &= \mathsf{manual}\ \mathsf{acupuncture},\ \mathsf{NT} &= \mathsf{no}\ \mathsf{treatment},\ \mathsf{SA} &= \mathsf{sham}\ \mathsf{acupuncture},\ \mathsf{SMD}\\ &= \mathsf{standardized}\ \mathsf{mean}\ \mathsf{difference},\ \mathsf{UC} &= \mathsf{usual}\ \mathsf{care},\ \mathsf{WA} &= \mathsf{warm}\ \mathsf{acupuncture},\ \mathsf{WM} &= \mathsf{Western}\\ \mathsf{medicine}. \end{aligned}$

Table 4

Pairwise meta-analysis of efficacy rate.

Comparison	Number	RR (95% CI)	Р	ľ
MA vs WM	2	1.10 [0.89, 1.37]	.3825	85.0%
MA vs UC	1	1.12 [0.93, 1.35]	.2335	-
EA vs SA	1	1.46 [0.80, 2.67]	.2204	_
EA vs WM	2	1.19 [0.99, 1.44]	.0621	69.6%
EA vs UC	1	1.17 [0.93, 1.48]	.1730	-
EA vs MA	15	1.12 [1.08, 1.17]	<.0001	0%
WA vs MA	5	1.13 [1.06, 1.20]	.0003	4.4%
WA vs EA	2	1.14 [1.00, 1.31]	.0580	0%
FA vs MA	2	1.28 [1.16, 1.42]	<.0001	0%
FA vs EA	1	1.22 [0.98, 1.52]	.0788	-
ACE vs MA	7	1.12 [1.05, 1.20]	.0009	42.4%
ACE vs EA	1	1.12 [0.93, 1.35]	.2335	-

ACE = acupoint catgut embedding, CI = confidence interval, EA = electroacupuncture, FA = fire acupuncture, MA = manual acupuncture, RR = relative risk, SA = sham acupuncture, UC = usual care, WA = warm acupuncture, WM = Western medicine.

Since the number of the included studies performed FA, WA, or ACE was <10, and these studies were assessed as being of low quality due to the presence of several bias risks, the effect size of each intervention was overestimated comparing with direct comparisons. Nevertheless, the differences in the relative effects between




Figure 4. Network plots for pain intensity (A), pain-related disability (B), and efficacy rate (C). ACE = acupoint catgut embedding, EA = electroacupunc-ture, FA = fire acupuncture, MA = manual acupuncture, NT = no treatment, SA = sham acupuncture, UC = usual care, WA = warm acupuncture, WM = Western medicine.

Fire acupuncture							
-0.70 (-2.43, 1.04)	Warm acupuncture						
-1.07 (-2.88, 0.74)	-0.37 (-1.42, 0.67)	Acupoint catgut embedding					
-1.16 (-2.83, 0.51)	-0.47 (-1.14, 0.20)	-0.09 (-1.02, 0.83)	Electroacupuncture				
-1.70 (-3.47, 0.07)	-1.00 (-1.98, -0.02)	-0.63 (-1.72, 0.47)	-0.53 (-1.38, 0.32)	Western medicine			
-1.76 (-3.37, -0.14)	-1.06 (-1.71, -0.41)	-0.69 (-1.50, 0.13)	-0.59 (-1.03, -0.15)	-0.06 (-0.79, 0.67)	Manual acupuncture		
-2.34 (-4.07, -0.60)	-1.64 (-2.54, -0.74)	-1.27 (-2.31, -0.23)	-1.17 (-1.91, -0.43)	-0.64 (-1.56, 0.28)	-0.58 (-1.22, 0.06)	Usual care	
-2.53 (-4.39, -0.66)	-1.83 (-2.93, -0.72)	-1.46 (-2.70, -0.22)	-1.36 (-2.32, -0.41)	-0.83 (-2.02, 0.36)	-0.77 (-1.71, 0.17)	-0.19 (-1.31, 0.94)	No treatment
-2.62 (-4.37, -0.87)	-1.92 (-2.86, -0.99)	-1.55 (-2.62, -0.48)	-1.46 (-2.23, -0.68)	-0.92 (-1.93, 0.08)	-0.86 (-1.55, -0.17)	-0.28 (-1.22, 0.65)	-0.09 (-1.16, 0.98) Sham acupuncture
Bold and indicate that SMD < (old and indicate that SMD < 0.00 is statistically significant.						

Table 5

Jo et al. • Medicine (2022) 101:33

Fire acupuncture								
-0.60 (-2.22, 1.02) -0.76 (-2.68, 1.16)	Electroacupuncture	Marm actinizativa						
-1.14 (-3.26, 0.97)	-0.54 (-1.91, 0.83)	-0.38 (-1.91, 1.14)	Western medicine					
-1.35 (-3.43, 0.72)	-0.75 (-2.05, 0.55)	-0.59 (-2.05, 0.87)	-0.21 (-1.83, 1.41)	Acupoint catgut embedding				
-1.35 (-3.16, 0.47)	-0.75 (-1.57, 0.07)	-0.59 (-1.85, 0.67)	-0.20 (-1.72, 1.31)	0.00 (-1.45, 1.46)	Sham acupuncture			
-1.52 (-3.73, 0.69)	-0.91 (-2.42, 0.59)	-0.76 (-2.56, 1.05)	-0.37 (-2.38, 1.63)	-0.16 (-2.12, 1.79)	-0.17 (-1.67, 1.33)	No treatment		
-1.68 (-3.44, 0.07)	-1.08 (-1.76, -0.40)	-0.92 (-1.88, 0.04)	-0.54 (-1.73, 0.65)	-0.33 (-1.44, 0.78)	-0.33 (-1.28, 0.61)	-0.17 (-1.78, 1.45)	Manual acupuncture	
-2.10 (-4.04, -0.16)	-1.49 (-2.56, -0.43)	-1.34 (-2.60, -0.07)	-0.95 (-2.40, 0.49)	-0.74 (-2.13, 0.64)	-0.75 (-2.00, 0.51)	-0.58 (-2.39, 1.23)	-0.41 (-1.24, 0.41)	Usual care
Bold and indicate that SMD < 0.00 is statistically significant.) is statistically significant.							

Fire acupuncture							
1.13 (0.99, 1.28)	Warm acupuncture						
1.16 (1.02, 1.31)	1.03 (0.94, 1.12)	Acupoint catgut embedding					
1.18 (1.05, 1.32)	1.05 (0.97, 1.13)	1.02 (0.95, 1.09)	Electroacupuncture				
1.30 (1.16, 1.45)	1.16 (1.08, 1.24)	1.12 (1.06, 1.19)	1.10 (1.06, 1.15)	Manual acupuncture			
1.37 (1.20, 1.55)	1.21 (1.10, 1.33)	1.18 (1.08, 1.29)	1.16 (1.08, 1.24)	1.05 (0.98, 1.12)	Western medicine		
1.43 (1.18, 1.73)	1.27 (1.07, 1.51)	1.23 (1.04, 1.46)	1.21 (1.03, 1.42)	1.10 (0.94, 1.29)	1.04 (0.88, 1.24)	Usual care	
1.72 (0.93, 3.20)	1.53 (0.83, 2.83)	1.49 (0.80, 2.75)	1.46 (0.79, 2.69)	1.32 (0.72, 2.44)	1.26 (0.68, 2.33)	1.21 (0.64, 2.27)	Sham acupuncture

Bold and indicate that RR > 1.00 is statistically significant.

Network meta-analysis comparisons of efficacy rate.

Table 7

18




Figure 5. Funnel plots for the network meta-analysis of pain intensity (A), pain-related disability (B), and efficacy rate (C). ACE = acupoint catgut embedding, EA = electroacupuncture, FA = fire acupuncture, MA = manual acupuncture, NT = no treatment, SA = sham acupuncture, UC = usual care, WA = warm acupuncture, WM = Western medicine.

interventions were acceptable, and the estimated effect size should not be taken, as it was in interpreting the results of this study.

While MA was effective in reducing pain intensity compared to SA, it was ranked lower than SA for decreasing

pain-related disability and was not significantly different in terms of the efficacy rate. These results contradict several previous reviews.^[13,14,91] Unlike the previous reviews; however, we included only SA designed with nonpenetrating acupuncture, resulting in insufficient direct comparison of SA and other acupuncture. Several types of SA were excluded in this study, such as the use of penetrating needles at locations away from true acupuncture points and the superficial insertion of needles. One review on the impact of SA in patients with pain found that the shallow insertion of needles at nonacupuncture points could have therapeutic activity for pain, albeit less effective than that obtained by deep insertion at a correct location.^[92] MacPherson et al suggested that there was no significant difference between shallow and deep needling when considering changes in fMRI.^[93] In addition, since shallow penetrating acupuncture (e.g., that with an intradermal needle) is already used as a treatment method, noninvasive SA was recently recommended as a sham control in RCT.^[92,94]

While 24 of the 65 included studies reported on the safety of interventions, there was no report of safety related to FA and only 1 study related to ACE, which ranked high in our network meta-analyses. FA is used to treat lateral epicondylitis,^[95] knee osteoarthritis,^[96] and ankle sprain,^[97] and may cause pain, burns, and skin rash due to a red-hot needle. There were few reports of adverse events to the FA in the previous studies,^[95-97] and Yeon et al^[98] reported that after FA, local third-degree burns were observed in the muscle and skin layers without any scarring, and the residual products present after FA did not exert toxicity, but rather increased cell growth. ACE has been used for the treatment of musculoskeletal pain, obesity, and facial palsy in Korea, China, and Taiwan.^[99] One review^[100] on the safety of ACE reported that the most common adverse events were induration, bleeding, fever, redness, and swelling, all of which disappeared without special treatment. Furthermore, the incidence of serious adverse events was 0.1%, which had no clear causal relationship with ACE. The evidence suggests that FA and ACE are safe treatment methods, but it is difficult to draw a clear conclusion on safety due to the small number of studies included. Thus, the safety of FA and ACE should be carefully assessed in further trials.

The present study has the following limitations. First, because of poor reporting, most of the included RCTs were considered to have an unclear risk of bias in their allocation concealment, blinding of participants and personnel, and blinding of outcome assessment. In addition, the sequences of 9 studies were randomly ordered based on the date of admission or visit, resulting in high risks of selection bias. Overall, the certainty of evidence obtained in our network meta-analyses was very low, largely because most of the included studies had considerable risks for bias and imprecision. Thus, further high-quality and larger-scale studies are needed. Second, it was difficult to assess the longterm effects of the interventions, as the studies varied in their follow-up periods. Third, we observed publication bias in our network meta-analysis of pain-related disability. Fourth, factors such as the selection of acupuncture points and variances in treatment methods (e.g., the numbers, frequencies, durations, and/or intervals of treatments) contributed to the high heterogeneity of our analyses. Despite these limitations, this study is the first network meta-analysis of RCTs to evaluate and rank the comparative effectiveness of various interventions for treating neck pain. More precisely designed, generated, and published RCTs are highly recommended.

5. Conclusion

The findings of our network meta-analyses indicate that FA, WA, ACE, and EA were more effective in relieving pain intensity and had higher efficacy rates than the other interventions (UC, SA, NT). We also show that FA, EA, and WA were more effective

than MA in pain intensity mitigation and the efficacy rate, and that EA reduced pain-related disability more effectively than MA. Overall, FA was found to be the best acupuncture method to reduce pain and disability index scores, while showing a high efficacy rate. However, higher-quality head-to-head trials comparing acupuncture therapies for treating neck pain are needed to confirm this conclusion. The findings of this review should be interpreted with caution given the low certainty of the evidence included in the 3 network meta-analyses.

Author contributions

Conceptualization: Hyo-Rim Jo, Eun-Ji Noh, Se-Hee Oh; Data curation: Su-Ji Choi: Formal analysis: Eun-Ji Noh, Seung-Ug Hong; Funding acquisition: Eun-Jung Kim; Methodology: Hyo-Rim Jo, Eun-Ji Noh, Se-Hee Oh; Project administration: Dong-Il Kim, Seung-Ug Hong; Supervision: Eun-Jung Kim; Writingoriginal draft: Hyo-Rim Jo; Writing-review&editing: Seong-Kyeong Choi, Won-Suk Sung, Eun-Jung Kim.

References

- Guzman J, Hurwitz EL, Carroll LJ, et al. A new conceptual model of neck pain: linking onset, course, and care: the bone and joint decade 2000-2010 task force on neck pain and its associated disorders. Spine. 2008;33:S14–23.
- [2] Blanpied PR, Gross AR, Elliott JM, et al. Neck pain: revision 2017: clinical practice guidelines linked to the international classification of functioning, disability and health from the orthopaedic section of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2017;47:A1–A83.
- [3] Wang WT, Olson SL, Campbell AH, et al. Effectiveness of physical therapy for patients with neck pain: an individualized approach using a clinical decision-making algorithm. Am J Phys Med Rehabil. 2003;82:203–18.
- [4] Peloso P, Gross A, Haines T, et al.; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007;CD0000319.
- [5] Childress MA, Becker BA. Nonoperative management of cervical radiculopathy. Am Fam Physician. 2016;93:746–54.
- [6] White AP, Arnold PM, Norvell DC, et al. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine. 2011;36:S131–43.
- [7] Chu HR, Hu J, Sun K, et al. Clinical practice guidelines of acupuncture-moxibustion for cervical spondylotic radiculopathy. World J Acupunct Moxibust. 2017;27:3–11.
- [8] Kjaer P, Kongsted A, Hartvigsen J, et al. National clinical guidelines for non-surgical treatment of patients with recent onset neck pain or cervical radiculopathy. Eur Spine J. 2017;26:2242–57.
- [9] Nahn RL, Barnes PM, Stussman BA. Expenditures on complementary health approaches: United States, 2012. Natl Health Stat Rep. 2016;95:1–11.
- [10] Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
- [11] Lee YJ, Kim MR, Lee EJ, et al. An evidence-based approach for the development of a clinical practice guideline for the treatment of neck pain using traditional Korean medicine. Eur J Integr Med. 2021;44:e101337.
- [12] Seo SY, Lee KB, Shin JS, et al. Effectiveness of acupuncture and electroacupuncture for chronic neck pain: a systematic review and meta-analysis. Am J Chin Med. 2017;45:1573–95.
- [13] Trinh KV, Graham N, Gross AR, et al. Acupuncture for neck disorders. Cochrane Database Syst Rev. 2006;CD004870.
- [14] Yuan QL, Guo TM, Liu L, et al. Traditional Chinese medicine for neck pain and low back pain: a systematic review and meta-analysis. PLoS One. 2015;10:e0117146.
- [15] Fu LM, Li JT, Wu WS. Randomized controlled trials of acupuncture for neck pain: systematic review and meta-analysis. J Altern Complement Med. 2009;15:133–45.
- [16] Seide SE, Jensen K, Kieser M. A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data. Res Synth Methods. 2020;11:363–78.
- [17] Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network

meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84.

- [18] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097–6.
- [19] Jo HR, Noh EJ, Oh SH. The effectiveness of different acupuncture therapies for neck pain: A protocol for systematic review and/or network meta-analysis. Medicine. 2021;100:e25379e25379.
- [20] Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
- [21] Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9:e99682.
- [22] Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011;64:1303–10.
- [23] Puhan MA, Schünemann HJ, Murad MH, et al. A grade working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
- [24] Raeissadat SA, Rayegani SM, Sadeghi F, et al. Comparison of ozone and lidocaine injection efficacy vs dry needling in myofascial pain syndrome patients. J Pain Res. 2018;11:1273–9.
- [25] Tabatabaiee A, Ebrahimi-Takamjani I, Ahmadi A, et al. Comparison of pressure release, phonophoresis and dry needling in treatment of latent myofascial trigger point of upper Trapezius muscle. J Back Musculoskelet Rehabil. 2019;32:587–94.
- [26] Nejati P, Mousavi R, Angoorani H. Acupuncture is as effective as exercise for improvement of chronic neck pain: a Randomized Clinical Trial. Shiraz E-Med J. 2021;22:e97497.
- [27] Ziaeifar M, Arab AM, Mosallanezhad Z, et al. Dry needling versus trigger point compression of the upper trapezius: a randomized clinical trial with two-week and three-month follow-up. J Man Manip Ther. 2019;27:152–61.
- [28] Ziaeifar M, Arab AM, Nourbakhsh MR. Clinical effectiveness of dry needling immediately after application on myofascial trigger point in upper trapezius muscle. J Chiropr Med. 2016;15:252–8.
- [29] Ziaeifar M, Arab AM, Karimi N, et al. The effect of dry needling on pain, pressure pain threshold and disability in patients with a myofascial trigger point in the upper trapezius muscle. J Bodyw Mov Ther. 2014;18:298–305.
- [30] Arias-Buría JL, Monroy-Acevedo A, Fernández-de-Las-Peñas C, et al. Effects of dry needling of active trigger points in the scalene muscles in individuals with mechanical neck pain: a randomized clinical trial. Acupunct Med. 2020;38:380–7.
- [31] Mejuto-Vázquez MJ, Salom-Moreno J, Ortega-Santiago R, et al. Shortterm changes in neck pain, widespread pressure pain sensitivity, and cervical range of motion after the application of trigger point dry needling in patients with acute mechanical neck pain: a randomized clinical trial. J Orthop Sports Phys Ther. 2014;44:252–60.
- [32] Garcia-de-Miguel S, Pecos-Martin D, Larroca-Sanz T, et al. Short-term effects of pens versus dry needling in subjects with unilateral mechanical neck pain and active myofascial trigger points in levator scapulae muscle: a randomized controlled trial. J Clin Med 2020;9:1665.
- [33] Tekin L, Akarsu S, Durmuş O, et al. The effect of dry needling in the treatment of myofascial pain syndrome: a randomized double-blinded placebo-controlled trial. Clin Rheumatol. 2013;32:309–15.
- [34] Hayta E, Umdu NM. A randomized trial to study the comparison of trigger point dry needling versus kinesio taping technique in myofascial pain syndrome during a 3-month follow up. Int J Physiother. 2016;3:540–6.
- [35] Chou LW, Hsieh YL, Chen HS, et al. Remote therapeutic effectiveness of acupuncture in treating myofascial trigger point of the upper trapezius muscle. Am J Phys Med Rehabil. 2011;90:1036–49.
- [36] Nabeta T, Kawakita K. Relief of chronic neck and shoulder pain by manual acupuncture to tender points—a sham-controlled randomized trial. Complement Ther Med. 2002;10:217–22.
- [37] Irnich D, Behrens N, Molzen H, et al. Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain. BMJ. 2001;322:1574–8.
- [38] Cho JH, Nam DH, Kim KT, et al. Acupuncture with non-steroidal anti-inflammatory drugs (NSAIDs) versus acupuncture or NSAIDs alone for the treatment of chronic neck pain: an assessor-blinded randomised controlled pilot study. Acupunct Med. 2014;32:17–23.
- [39] De Meulemeester KE, Castelein B, Coppieters I, et al. Comparing trigger point dry needling and manual pressure technique for the management of myofascial neck/shoulder pain: a randomized clinical trial. J Manipulative Physiol Ther. 2017;40:11–20.
- [40] Chen L, Deng H, Houle T, et al. A randomized trial to assess the immediate impact of acupuncture on quantitative sensory testing, pain, and functional status. Pain. 2019;160:2456–63.

- [41] Ho LF, Lin ZX, Leung AWN, et al. Efficacy of abdominal acupuncture for neck pain: a randomized controlled trial. PLoS One. 2017;12:e0181360.
- [42] Wang CM, Chen HW, Wang YW, et al. Therapeutic observation of acupuncture at myofascial trigger points for cervical spondylosis of vertebral artery type. Shanghai J Acupuncture Moxibustion. 2015;34:48–50.
- [43] Fu WB, Zhang HL, Zhu XP, et al. Randomized controlled study on picking therapy for treatment of cervical spondylosis. Chin Acupuncture Moxibustion. 2005;25:607–9.
- [44] Fu HL, Qu SS, Chen JQ, et al. A clinical randomized controlled study on the curative effect of abdominal acupuncture combined with Mckenzie therapy in the treatment of cervical spondylopathy. J Practical Med. 2013;29:650–2.
- [45] Cui QS. A contrastive study of EA and sham EA for neck pain of cervical spondylosis (Masters dissertation). Guangdong Province, China: Guangzhou University of Chinese Medicine, 2016.
- [46] Feng X. Placebo effect of electrical acupuncture in chronic neck pain: a randomized clinical trial (Masters dissertation). Guangdong Province, China: Guangzhou University of Chinese Medicine, 2014.
- [47] Zhang SP, Chiu TT, Chiu SN. Long-term efficacy of electroacupuncture for chronic neck pain: a randomised controlled trial. Hong Kong Med J. 2013;19(Suppl 9):36–9.
- [48] Li JP. Electro-acupuncture treatment of cervical disease in clinical research. J Liaoning University Tradit Chin Med. 2008;10:124–5.
- [49] Yan SM. Observation on the short-term and long-term curative effect of electric acupuncture on 78 cases of cervical spondylotic radiculopathy. Fujian J Traditi Chin Med. 2006;37:35.
- [50] Diethelm P. Clinical study of acupuncture treatment of chronic recurrent nonspecific cervical disease with kinesio-taping (Doctoral thesis). Shandong Province, China: Shandong University of Traditional Chinese Medicine, 2014.
- [51] Yang DD. Clinical observation on the changes of serum IL-6 in patients with cervical n spondylotic radiculopathy by short acupuncture combined with electroacupuncture (Masters dissertation). Jiangsu Province, China: Nanjing University of Traditional Chinese Medicine, 2020.
- [52] Huang W, Jiang A. Effects on cervical spondylosis of neck type treated with Hegu needling and Shu needling techniques at the positive reaction points. Zhongguo Zhen Jiu 2018;38:1157–60.
- [53] Chen YR. Clinical observation of the therapeutic effect of electro-acupuncture with abdominal acupuncture in treating cervical spondylosis of nerve root type (Masters dissertation). Guangdong Province, China: Guangzhou University of Chinese Medicine, 2016.
- [54] Chen GL. The Clinical efficacy observation on electroacupuncture at cervical jiaji points for neck type of cervical spondylosis (Masters dissertation). Heilongjiang Province, China: Heilongjiang University of Traditional Chinese Medicine, 2016.
- [55] Tian HZ, Sun ZR, Zhang QH. Observation of therapeutic effect on cervical Jiaji electroacupuncture treatment of nerve root type cervical spondylosis. J Emerg Traditi Chin Med. 2015;24:1050–2.
- [56] Chen L, Jiang W, Guan XF, et al. Clinical efficacy of Fangshi scalp acupuncture for treating cervical spondylotic. Shijie Zhong Yi Yao. 2015;10:1768–70.
- [57] Liu XF. Clinical observation of nerve root type cervical spondylosis treatment EA jiaji. Heilongjiang: Heilongjiang University of Chinese Medicine. 2014.
- [58] Jin DS. Clinical observation on treatment of cervical spondylotic radiculopathy by electro-acupuncture. Nanjing: Nanjing University of Chinese Medicine. 2013.
- [59] Zhang CP. Observation on therapeutic effect of electric nape acupuncture on cervical spondylopathy. Qiu Yi Wen Yao. 2011;9:530.
- [60] Yang XB, Ou YK, An JM. Electroacupuncture for 36 cases of nerve root cervical spondylopathy. Zhongyi Wai Zhi Za Zhi. 2011;21:30–1.
- [61] Ji BJ, Zhou ZQ, Huang MJ. The efficacy of different waveforms of electrical acupuncture on neck pain of cervical spondylosis. Baojian Yi Xue Yan Jiu Yu Shi Jian. 2015;12:39–43.
- [62] Wang WX. Clinical research on cervical spondylopathy and neck pain treating with electro-acupuncture, acupuncture. Guangzhou: Guangzhou University of Chinese Medicine, 2010.
- [63] Liu SL. Clinical study on treatment of cervical spondylosis of nerve-root type by electroacupuncture at jiaji point. Heilongjiang: Heilongjiang University of Chinese Medicine, 2010.
- [64] Lai RX. Clinical study of treating cervical spondylotic radiculopathy with electric needle acupuncture. Guangzhou: Guangzhou University of Chinese Medicine, 2010.
- [65] Yang YZ, Wang C. Evaluation of therapeutic effect of electroacupuncture on nerve root cervical spondylopathy. Zhong Yi Yao Xin Xi. 2009;26:69.

- [66] Ding ZG. Clinical research of electro-acupuncture of jiaji points on cervicalspondylotic radiculopathy. Nanjing: Nanjing University of Chinese Medicine. 2009.
- [67] Yu ZG. Clinical study on treatment of cervical spondylosis of nerve-root type by electroacupuncture at jiaji point. Heilongjiang: Heilongjiang University of Chinese Medicine. 2007.
- [68] Chen JB, Zheng JL, Wu XQ. Clinical study on treatment of cervical cervical spondylosis with warm needling at bamai jiaohui points. Shi Yong Zhong Yi Neike Za Zhi. 2020;34:76–9.
- [69] Ju D, Cheng WQ. Efficacy of silver needle with heat conduction therapy on cervical spondylotic radiculopathy. Jones Jo
- [70] Xu JF. Effects of warm acupuncture at jiaji points on nerve root type cervical spondylosis. Zhong Yi Lin Chuang Yan Jiu. 2017;32:89–90.
- [71] Guo DD. Clinical Study on Cervicodynia of Cervical-type Cervical Spondylopathy with Electronic Wam needle. Guangzhou: Guangzhou University of Chinese Medicine. 2015.
- [72] Zhou JF, Li XW, Zhao JC, et al. Treatment of 30 patients with cervical spondylotic radiculopathy by acupuncture plus warming-needle. Shijie Zhen Jiu Za Zhi. 2014;24:24–8.
- [73] Lin ZX. Clinical study on electrothermal acupuncture treatment of cervical spondylopathy of nerve root type. Beijing: Beijing University of Chinese Medicine. 2012.
- [74] Garov Y. The effectiveness and safety of electro-acupuncture and warm acupuncture for the treatment of cervical spondylotic radiculopathy. Nanjing: Nanjing University of Chinese Medicine. 2016.
- [75] Su CX, Lin F, Jiang ZL. Therapeutic observation of warm needling for neck-back myofascial pain syndrome. Shang Hai Zhen Jiu Za Zhi. 2015;34:1102–5.
- [76] Lin JS. Clinical observation on warm needle moxibustion for the treatment of the cervical spondylopathy. Guangzhou: Guangzhou University of Chinese Medicine. 2012.
- [77] Qui C, Zhang ZQ. Observation on curative effect of fire needle on nerve root cervical spondylopathy. Si Chuan Zhongyi. 2015;12:173–4.
- [78] Sun YJ, Wu YC, Zhang JF, et al. Therapeutic observation of LU's heat-producing needling (Shao Shan Huo) for cervical spondylotic radiculopathy. Shang Hai Zhen Jiu Za Zhi. 2015;34:234–6.
- [79] Zhao MH. The study of fire-needle therapy on the cervical type cervical spondylosis. Guangzhou: Guangzhou University of Chinese Medicine. 2013.
- [80] Cheng SZ. Clinical observation on the treatment of nerve root cervical spondylopathy by catgut embedding at acupoints of five elements and eight diagrams (Hou Tian) at the umbilical. Shi Yong Zhong Yi Yao Za Zhi. 2018;34:1114–5.
- [81] Qui C, Zhao CX, Wang TT, et al. Study on the clinical effect of catgut embedding at positive acupoints in the treatment of cervical spondylotic radiculopathy. Ha Bei Zhong Yi Yao Xue Bao. 2015;30:55–7.
- [82] Wang H, Sun WS, Wang YM, et al. Clinical observations on microinvasive thread embedding for the treatment of neck pain due to cercical spondylosis. Shang Hai Zhen Jiu Za Zhi. 2016;35:1494–6.
- [83] Li RQ, Wang BJ, Sun LX, et al. Observation on therapeutic effect of catgut embedding at acupoints on nerve root cervical spondylopathy. Xian Dai Zhong Xi Yi Jie He Za Zhi. 2015;24:3685–7.
- [84] Zhao Z, Zhao XX. Clinical research of catgut embedding and acupuncture treatment for cervical spondylosis. Zhong Yi Xue Bao. 2015;30:449.
- [85] Ding M, Jiang YQ, Feng H, et al. Therapeutic observation on micro-invasive thread-embedding therapy for cervical spondylosis of nerve root type. Shang Hai Zhen Jiu Za Zhi. 2012;31:900–1.
- [86] Feng H, Ding M, Jiang YQ, et al. Study on the efficacy and safety of minimally invasive thread embedding therapy in the treatment of nerve root cervical spondylopathy. Jiang Su Zhong Yi Yao. 2012;44:59–60.
- [87] Xian YD. Clinical research of cervical spondylotic radiculopathy with acupoint catgut embedding therapy. Guangzhou: Guangzhou University of Chinese Medicine. 2012.
- [88] Zou HH. Clinical research of cervical spondylotic radiculopathy with acupoint catgut embedding therapy. Guangzhou: Guangzhou University of Chinese Medicine. 2016.
- [89] Huang CJ, Huang YJ, Chen CY. The origin and development of fire. Chin Acupunctue Moxibustion. 2013;33:455–8.
- [90] Zhang XX, Wu ZH, Dong MX. Preliminary study on curing mechanism of fire needle therapy. Beijing J Trad Chin Med. 2007;2007:576–8.
- [91] Navarro-Santana MJ, Sanchez-Infante J, Fernández-de-Las-Peñas C, et al. effectiveness of dry needling for myofascial trigger points associated with neck pain symptoms: an updated systematic review and meta-analysis. J Clin Med. 2020;9:3300.

- [93] MacPherson H, Green G, Nevado A, et al. Brain imaging of acupuncture: comparing superficial with deep needling. Neurosci Lett. 2008;434:144–9.
- [94] Jang JY, Kim SJ, Kim NS, et al. Review of analysis of sham acupuncture in acupuncture clinical trials. J Acupunct Res. 2011;28:29–38.
- [95] Wu SY, Lu CN, Chung CJ, et al. Therapeutic effects of acupuncture plus fire needle versus acupuncture alone in lateral epicondylitis: a randomized case-control pilot study. Medicine (Baltim). 2019;98:e15937.
- [96] Ko HJ, Yoo JH, Shin JC. A systematic review and meta-analysis of fire needling treatment for knee osteoarthritis: focused on comparative

studies with manual acupuncture treatment during recent five years. Korean J Acupuncture. 2019;36:104–14.

- [97] Ko HJ, Yoo JH, Kim MW, et al. Systematic review of fire needling or warm needling treatment for ankle sprain. Acupunct Res. 2020;37:19–27.
- [98] Yeon SH, Lee SB, Kwon OS, et al. The safety assessment of fire needling. Korean J Oriental Med. 2012;18:103–10.
- [99] Cho Y, Lee S, Kim J, et al. Thread embedding acupuncture for musculoskeletal pain: a systematic review and meta-analysis protocol. BMJ Open. 2018;8:e015461.
- [100] Huang JJ, Liang JQ, Xu XK, et al. Safety of thread embedding acupuncture therapy: a systematic review. Chin J Integr Med. 2021;27:947–55.